Everyone is talking about these popular health foods. How good for you are they? Find out from Food Network.

For maximum benefit, drink this combination between one and 3 times a day. It will also be utilized in cooking, salad dressings, mayonnaise or combined with greens. good article HOWEVER Im almost one hundred{6027822517f6a24aa6782b21721112a1dd7e3dff3f7f31ba554079a53b833a6f} certain that you are the one person on earth who can eat garlic with these stomach problems. like severely I will likely be coughing and burping up blood if I eat garlic and OMG tomatoes.. not too many they’re very acidic!! and high in glutamate. but tomato ketchup and many others is a given. In addition to the breakfast, I attempt to discover healthy snacks that I like. Some of my favorites are hummus and crackers, chips and salsa, and ants on a log.

Based in 1994, Dynamic Health supplies a range of health dietary supplements and …

Read More

Employee wellness company Wellable acquired DailyEndorphin, which offers corporate wellness challenges in which employees can set up group fitness or nutrition programs and invite their colleagues to participate. 

DailyEndorphin offers challenges for exercise, step count, nutrition, weight and hydration.

Boston-based Wellable will add DailyEndorphins assets to its Wellable Wellness Platform, which also includes an incentive program and support model, a personal wellness assessment and clinical event verifications (where flu shots and preventative care are verified). The employee-focused company also has health content and on-demand classes.

“We are thrilled to support the next chapter for DailyEndorphin and welcome them to our thriving Wellable community. DailyEndorphin was a pioneer in the wellness challenge industry, and we look forward to delivering customizable, affordable and effective wellness programs for their customers,” Geoff Geredien, chief growth officer of Wellable, said in a statement.

THE LARGER TREND

In September, Wellable acquired Sweat Factor, a fitness

Read More

The U.S. International Trade Commission ruled Thursday that Apple Watches with ECG functionality violate two AliveCor patents, but the agency put an import ban on hold.

The ITC issued a limited exclusion order prohibiting further imports and a cease and desist order against Apple. It also set a bond of $2 per unit imported or sold during the Presidential review period. However, enforcement of those orders, including the bond, is suspended until the case before the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board is resolved.

The decision comes weeks after the PTAB ruled three AliveCor patents regarding the detection of heart conditions like cardiac arrhythmias were not patentable, citing earlier advancements that made the technology “obvious.” AliveCor appealed that decision. 

The final determination by the ITC was set to come down earlier this month, but Apple petitioned to suspend or delay the order due to the PTAB

Read More

As 2022 comes to a close, MobiHealthNews asked executives from across the digital health industry about their biggest takeaways from the year. 

Check out their insights below on topics ranging from improving health equity to the continued use of virtual healthcare, especially for behavioral and mental health.

Chris Brickler, cofounder and CEO of MyndVR

“It’s important not to get comfortable. In early to mid-2022, there was a huge amount of speculation – in digital healthcare, unicorns became a little less rare. Towards the end of the year, things took a drastic shift. To be completely honest, over the last two years, a lot of companies, in digital health or otherwise, had unreasonable and unrealistic valuations, and we’re seeing the consequences of that now. In healthcare, you could put the word ‘digital’ in front of whatever product you were trying to sell and increase your valuation by a $100 million overnight.

Read More

Pharma company Boehringer Ingelheim and Click Therapeutics announced an expanded partnership to develop and commercialize another prescription digital therapeutic for patients with schizophrenia.

The deal will net Click up to $460 million, plus tiered royalties. It builds on an earlier collaboration announced in 2020 that developed CT-155, an initial therapeutic for schizophrenia.

The companies said CT-155 has met its development milestones to date, and it’s generated supportive evidence in clinical learning studies. They also noted that a pivotal registration study for the initial therapeutic is upcoming.

“Expanding our successful partnership with Boehringer Ingelheim enables our team to build on the experience and insights gathered with CT-155 and further expand the scope of our digital therapeutics platform,” Austin Speier, Click’s chief strategy officer, said in a statement. “This growing collaboration is a testament to the progress we have achieved so far working together and creates the inspiring opportunity to expand CT-155

Read More